New GLP-1 Drug Design Shows Superior Weight Loss in Mice
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
Summary
Researchers discovered that optimizing GLP-1 receptor signaling bias, rather than maximizing potency, leads to superior weight loss. A new compound called NNC5840 demonstrated greater weight reduction than semaglutide in obese mice by exhibiting partial, cAMP-biased signaling. This challenges the traditional drug development approach of maximizing receptor activation and suggests that balanced consideration of multiple signaling pathways could yield more effective obesity treatments.
Detailed Summary
This groundbreaking study from Novo Nordisk researchers challenges the fundamental approach to developing GLP-1 receptor agonists for obesity treatment. While current drugs like semaglutide were engineered for maximum potency at activating cAMP signaling, this research reveals that a more nuanced approach considering signaling bias produces superior results.
The team tested five GLP-1 receptor agonists in diet-induced obese mice over 14 days, measuring both in vitro signaling properties and in vivo weight loss (ranging from -11.81% to -23.22%). Surprisingly, cAMP signaling potency showed no correlation with weight loss efficacy (R² = 0.13, p = 0.47), while the signaling bias metric β showed strong correlation (R² = 0.91, p = 0.01).
The novel compound NNC5840 exemplifies this principle. Despite having partial Gsα signaling and reduced cAMP potency compared to semaglutide, NNC5840 achieved superior maximal weight reduction in obese mice. The compound exhibits cAMP-biased signaling, meaning it preferentially activates beneficial cAMP pathways while minimizing β-arrestin recruitment associated with receptor desensitization.
These findings suggest that drug discovery should focus on optimizing the balance between different receptor signaling pathways rather than simply maximizing activation of a single pathway. This could lead to more effective obesity medications with improved therapeutic profiles.
However, the study has limitations including unknown effects of structural modifications on drug properties and the need for human clinical validation. The research was conducted by Novo Nordisk employees, presenting potential conflicts of interest in interpreting results favoring novel compounds over existing therapies.
Key Findings
- Signaling bias metric β strongly correlated with weight loss (R² = 0.91, p = 0.01) while cAMP potency showed no correlation (R² = 0.13, p = 0.47)
- NNC5840 achieved superior maximal weight reduction compared to semaglutide in diet-induced obese mice over 14 days
- Weight loss across five GLP-1 agonists ranged from -11.81% to -23.22% in obese mice
- NNC5840 exhibits partial Gsα signaling with cAMP-biased receptor activation profile
- Biased agonists showed greater weight loss despite reduced cAMP signaling potency compared to balanced agonists
- Study included 8 mice per treatment group with statistical analysis using 2-way ANOVA
- Pharmacokinetic analysis revealed distinct exposure profiles between NNC5840 and semaglutide
Methodology
The study used diet-induced obese C57B6/J mice (n=8 per group) treated with daily subcutaneous injections for 14 days. In vitro signaling was assessed using CRE-Luciferase reporter assays for cAMP and BRET-based assays for β-arrestin recruitment. Statistical analysis employed 2-way ANOVA with Tukey's post-hoc correction. Pharmacokinetic profiles were determined using sparse sampling and LC-MS/MS analysis.
Study Limitations
The study was conducted entirely in mice, requiring human clinical validation. All authors are Novo Nordisk employees, creating potential conflicts of interest. The research doesn't address how structural modifications affect drug physicochemical properties, and weight loss measurements may not have reached maximum efficacy (Emax) for all compounds tested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.